Elizabeth Budde, M.D., Ph.D. is a well-recognized clinical expert and researchers in the area of blood cancers. Her academic and clinical interests center on novel treatment for patients with lymphoma and leukemia. As a physician scientist, she leads a group of talented researchers designing and investigating the use of immunotherapy to treat blood cancers and other diseases.
She leads the Immunotherapy Modality Team and is the executive medical director, Enterprise Immune Effector Cell Program at City of Hope National Medical Center. She also serves as a member on several national committees including National Comprehensive Cancer Network (NCCN) guidelines for B Cell Lymphoma, NCCN guidelines for Management of Immunotherapy-related Toxicities, and Alliance of American Cancer Institute CAR T Working Group.
Dr. Budde has received many honors and awards for her work. She was chosen as a Special Fellow in Clinical Research awardee by The Leukemia & Lymphoma Society, and an awardee of the Stop Cancer Foundation seed grant in 2016. She is also a recipient of the prestigious Damon Runyon Cancer Research Foundation Clinical Investigator Award (2014-2019). She has published many peer-reviewed articles in prominent journals including the Lancet Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, and Journal of Immunology.  She has also given many invited presentations at national and international meetings on her work.